Simulations Plus, Inc. SLP

Company Overview

Simulations Plus, Inc. is a publicly traded biotechnology and software company that develops modeling and simulation software and provides consulting services to support drug discovery, development, regulatory approval, and commercialization. The company primarily operates within the pharmaceutical, biotechnology, and regulatory science industries, focusing on quantitative methods that predict drug behavior in humans. Its core value proposition lies in reducing development timelines, costs, and clinical risk through advanced computational modeling.

The company’s primary revenue drivers include proprietary software platforms for pharmacokinetics and pharmacodynamics modeling, physiologically based pharmacokinetic (PBPK) modeling, population PK/PD analysis, and specialized regulatory and clinical pharmacology consulting services. Simulations Plus serves a global customer base that includes large pharmaceutical companies, emerging biotechnology firms, academic institutions, and government agencies. Founded in 1996, the company initially focused on chemical modeling and cheminformatics before evolving into a leader in pharmacometric and systems-based modeling through organic development and targeted acquisitions.